文献速递主动脉疾病

无并发症亚急性B型主动脉夹层TEVAR的IRAD登记研究结局

Outcomes of thoracic endovascular aortic repair for uncomplicated subacute type B aortic dissection in the IRAD registry.
PubMed 文献 · J Vasc Surg · 2026-09-28

基于IRAD数据库1996年1月至2023年9月的无并发症B型急性主动脉夹层患者,比较亚急性期(15-90天)TEVAR与最佳药物治疗的结局。4年生存率两组相似(87% vs 84%,P=.925),但sTEVAR组3年内新发夹层率更高(13.9% vs 4.8%,P=.002),均发生于TEVAR后1年内。

要点

  • 无并发症B型夹层亚急性期TEVAR与药物治疗4年生存率相似。
  • sTEVAR组3年内新发夹层率显著高于BMT组,且均发生于术后1年内。
  • 夹层进展、动脉瘤样变、再干预、破裂、卒中及再住院率两组相当。

核心结论

  • 与最佳药物治疗相比,亚急性期TEVAR的4年生存率相似。
  • sTEVAR组新发夹层率更高,均发生于TEVAR后1年内。

研究设计与样本

  • 国际急性主动脉夹层登记(IRAD)数据库回顾性查询,1996年1月至2023年9月。
  • 纳入无并发症B型急性主动脉夹层患者,比较亚急性期(15-90天)TEVAR(63例,4.6%)与BMT(1310例,95.4%)。
  • 主要结局为4年生存率,次要结局包括延迟干预、夹层进展、新发夹层、再住院、破裂及卒中。

主要发现

  • 4年生存率sTEVAR组87% vs BMT组84%,P=.925。
  • 3年新发夹层率sTEVAR组13.9% vs BMT组4.8%,P=.002,均发生于TEVAR后1年内。
  • 夹层进展、动脉瘤样变、再干预、破裂、卒中及再住院率两组相当。

临床怎么用

  • 对于无并发症亚急性B型主动脉夹层,TEVAR与BMT生存率相似,但需警惕术后1年内新发夹层风险。
  • TEVAR可能在该人群中有一定作用,但需随机试验确定获益患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thoracic endovascular aortic repair (TEVAR) for uncomplicated type B acute aortic dissection (TBAAD) remains controversial. Compared with best medical therapy (BMT), TEVAR has demonstrated benefits for aortic remodeling; however, this intervention has procedure-related risks. METHODS: The International Registry of Acute Aortic Dissection database was queried from January 1996 to September 2023 for all uncomplicated TBAAD cases. Patients receiving TEVAR during the subacute phase (sTEVAR; 15-90 days) and BMT were included in this study. Baseline comorbidities were recorded. The primary outcome was survival at 4 years. The secondary outcomes included delayed aortic interventions, progression of aortic disease, new dissection, rehospitalization, rupture, and stroke. RESULTS: During the study period, 1373 patients with uncomplicated TBAAD were entered into the registry and had follow-up data available. In addition, 63 patients (4.6%) underwent sTEVAR, and 1310 (95.4%) received BMT. The 4-year survival rate was similar between the groups (sTEVAR 87% vs BMT 84%, P = .925). At 3 years, the sTEVAR group had higher rates of new dissection (13.9% vs 4.8%, P = .002), all within 1 year of TEVAR. Progression of dissection, aneurysmal degeneration, reintervention, rupture, stroke, and rehospitalization were comparable between the groups. CONCLUSIONS: Compared with BMT, sTEVAR led to similar survival rates. New dissection was higher in the sTEVAR group. TEVAR may have a role in uncomplicated subacute TBAAD, and further randomized trials are essential to identify which patients benefit from this intervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gontarz B, Leshnower B, Arnaoutakis G, et al. Outcomes of thoracic endovascular aortic repair for uncomplicated subacute type B aortic dissection in the IRAD registry. J Vasc Surg. 2026. PMID: 42805273. doi:10.1016/j.jvs.2026.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。